hausarzt update basel
donnerstag | 7.11.2019
08.30–18.00 Uhr | missionsstrasse 21, basel

Neue Orale Antikoagulanzien

Die Qual mit der Wahl und alltägliche Herausforderungen

PD Dr. med. Gregor Leibundgut

Leiter Kardiologie KSBL

09:15-09:45

Indikationen für eine OAK

- Nicht-ischämische Herzkrankheiten (41%)
  - Vorhofflimmern ist heute die häufigste Indikation für eine OAK
- venöse Thromboembolien (14%)
- ischämische Herzkrankheiten (13%)
- übrige Diagnosen (31%)
  - dilatative Kardiomyopathie
  - kardialer Thrombus nach Myokardinfarkt
  - arterielle Thrombosen



“Blutverdünnende” Substanzen

Antiplatelet drugs	Glycoprotein IIb/IIIa	Abciximab, Eptifibatide, Tirofiban, Roxifiban, Orbofiban	
	P_2Y_{12} inhibitors (ADP receptor)	Thienopyridines: Clopidogrel, Prasugrel, Ticlopidine Nucleotide/nucleoside analogs: Cangrelor, Elinogrel, Ticagrelor	
	Prostaglandin analogue (PGI2)	Beraprost, Iloprost, Prostacyclin, Treprostinil	
	COX inhibitors	Aspirin, Aloxiprin, Carbasalate calcium, Indobufen, Triflusal	
	Thromboxane inhibitors	Thromboxane synthase inhibitors: Dipyridamole (+Aspirin), Picotamide Receptor antagonists: Terutroban	
	Phosphodiesterase	Cilostazol, Dipyridamole, Triflusal	
	Other	Cloricromen, Ditazole, Vorapaxar	
Anticoagulants	**Vitamin K antagonists (inhibit II, VII, IX, X)**	**Coumarins**: Acenocoumarol Coumatetralyl Dicoumarol Ethyl biscoumacetate Phenprocoumon Warfarin 1,3-Indandiones: Clorindione Diphenadione Phenindione Other: Tioclomarol	
	Factor Xa inhibitors (with some II inhibition)	Heparin group glycosaminoglycans (bind antithrombin)	LMWH: Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin Oligosaccharides: Fondaparinux, Idraparinux Heparinoids: Danaparoid, Dermatan sulfate, Sulodexide
		Direct Xa inhibitors	Xabans: **Apixaban**, Betrixaban, Darexaban, **Edoxaban**, Otamixaban, **Rivaroxaban**
	Direct thrombin (IIa) inhibitors	Bivalent: Hirudin, Bivalirudin, Desirudin, Lepirudin Univalent: Argatroban, **Dabigatran**, Melagatran, Ximelagatran	
	Other	Antithrombin III, Defibrotide, Protein C (Drotrecogin alfa), Ramatroban, REG1	
Thrombolytic drugs/ fibrinolytics	Plasminogen activators: r-tPA (Alteplase, Reteplase, Tenecteplase), uPA (Saruplase, Urokinase), Anistreplase, Monteplase, Streptokinase, Other serine endopeptidases: Ancrod, Brinase, Fibrinolysin		
Non-medicinal	Citrate, EDTA, Oxalate		

Entwicklung der Antikoagulanzien



Wirkungsprinzipien







Vitamkin K-abhängige Gerinnungsfaktoren: II, VII, IX, X

Indikationen und Dosis

Stroke prevention in atrial fibrillation (SPAF)		
	Standard dose	**Comments/dose reduction**
Apixaban[30]	2 × 5 mg	2 × 2.5 mg if two out of three: weight ≤60 kg, age ≥80 years, serum creatinine ≥133 µmol/(1.5 mg/dL) [*or* if CrCl 15–29 mL/min]
Dabigatran[28]	2 × 150 mg / 2 × 110 mg	No pre-specified dose-reduction criteria[a]
Edoxaban[31]	1 × 60 mg	1 × 30 mg if: weight ≤60 kg, CrCl ≤50 mL/min, concomitant therapy with strong P-Gp inhibitor (see **chapter 5**)
Rivaroxaban[29]	1 × 20 mg	1 × 15 mg if CrCl ≤50 mL/min
Treatment of DVT/PE		
	Initial therapy	**Remainder of treatment phase**
Apixaban[330]	2 × 10 mg, 7 days	2 × 5 mg, no dose reduction
Dabigatran[331]	Heparin/LMWH	No pre-specified dose-reduction criteria[b]
Edoxaban[332]	Heparin/LMWH	1 × 60 mg, same dose reduction as for SPAF (see above)
Rivaroxaban[333,334]	2 × 15 mg, 21 days	1 × 20 mg, no dose reduction[c]
Long-term prevention of recurrent DVT/PE (i.e. after 6 months)		
	Standard dose	**Comments/dose reduction**
Apixaban[335]	2 × 2.5 mg	
Dabigatran[336]	2 × 150 mg	No pre-specified dose-reduction criteria[d]
Edoxaban	not specifically studied	
Rivaroxaban[337]	1 × 10 mg	e

VTE prevention post-major orthopaedic surgery		
	Standard dose	**Comments/dose reduction**
Apixaban[338]	2 × 2.5 mg	
Dabigatran[339,340]	1 × 220 mg	f
Edoxaban[341,342]	1 × 30 mg	Not approved in Europe (only studied in Asia)
Rivaroxaban[343–346]	1 × 10 mg	
Stroke prevention post-PCI (with concomitant atrial fibrillation)[g]		
	Standard dose	**Comments/dose reduction**
Apixaban	To be determined (pending results of AUGUSTUS trial)	
Dabigatran[141]	150 mg BID or 110 mg BID	+Clopidogrel or Ticagrelor; no dose reduction
Edoxaban	To be determined (pending results of ENTRUST-AF PCI trial)[310]	
Rivaroxaban[308]	15 mg OD (+Clopidogrel)	Dose reduction to 10 mg OD if CrCl 30–49 mL/min
Secondary prevention of atherothrombotic events post-ACS (without AF)		
	Standard dose	**Comments/dose reduction**
Rivaroxaban[171]	2.5 mg BID	In addition to Aspirin ± $P2Y_{12}$ inhibitor
Secondary prevention of atherothrombotic events in stable CAD (without AF)[h]		
	Standard dose	**Comments/dose reduction**
Rivaroxaban[347]	2.5 mg BID	In addition to Aspirin[h]

Kardiale Ursache eines Schlaganfalls

Die Ursache eines Schlaganfalls liegt in 30% im Herzen

- Vorhofflimmern
- Klappenerkrankungen
- Kontraktionsstörungen/Wandaneurysmen mit Thromben
- Akuter Myokardinfarkt (inflammatorisch)
- Persistierendes foramen ovale (PFO)

Limitationen innerhalb Fachgebiet

Condition	Eligibility for NOAC therapy
Mechanical prosthetic valve	Contraindicated
Moderate to severe mitral stenosis (usually of rheumatic origin)	Contraindicated
Mild to moderate other native valvular disease (e.g., mild-moderate aortic stenosis or regurgitation, degenerative mitral regurgitation etc.)	Included in NOAC trials
Severe aortic stenosis	Limited data (excluded in RE-LY) Most will undergo intervention
Bioprosthetic valve (after > 3 months post operatively)	Not advised if for rheumatic mitral stenosis
	Acceptable if for degenerative mitral regurgitation or in the aortic position
Mitral valve repair (after > 3 months post operatively)	Some patients included in some NOAC trials
PTAV and TAVI	No prospective data yet May require combination with single or dual antiplatelet therapy
Hypertrophic cardiomyopathy	Few data, but patients may be eligible for NOACs

VHF ist eine progressive Erkrankung



Alternativen zur Antikoagulation?

- Pulmonalvenenisolation (PVI)
  - Kathetergestützt
  - Komplikationsrate 5-8%
  - Erfolgsrate 70-80% inkl. Re-Ablation

Symptomatisch, Rhythmuskontrolle, KEINE Schlaganfallreduktion

- Vorhofsohrverschluss (LAAC)
  - Kathetergestützt
  - Komplikationsrate 2-3%
  - Erfolgsrate 77% (PROTECT AF, PREVAIL)

Asymptomatisch, Schlaganfallreduktion

CHA_2DS_2-VASc Score

Letter	Clinical Characteristic	Points
C	Congestive Heart Failure	1
H	Hypertension	1
A2	Age ≥75	2
D	Diabetes Mellitus	1
S2	Stroke/TIA/TE	2
V	Vascular disease	1
A	Age 65-74	1
Sc	Sex category (female)	1
	Maximum score	9

LV = left ventricular; TIA = transient ischemic attack; TE = thromboembolism; vascular disease = prior myocardial infarction, peripheral artery disease, or aortic plaque

Points	Annual Adjusted Stroke Rate	
0	0%	low risk
1	1.3%	intermediate
2	2.2%	high risk
3	3.2%	
4	4.0%	
5	6.7%	
6	9.8%	
7	9.6%	
8	6.7%	
9	15.2%	

(N)OAK

HAS-BLED Score

Letter	Clinical Characteristic	Points
H	Hypertension	1
A	Abnormal renal &/or liver function (1 point each)	1 or 2
S	Stroke history	1
B	Bleeding	1
L	Labile INRs	1
E	Elderly (Age ≥65)	2
D	Drugs or alcohol (1 point each)	1 or 2
	Maximum score	9

Points	Annual Adjusted Bleeding Rate
0	1.13%
1	1.02%
2	1.88%
3	3.74%
4	8.70%
5	12.50%
Any	1.56%

Aspirin vs NOAK

- AVERROES trial (Apixaban vs ASS bei VHF)





Connolly SJ et al. N Engl J Med. 2011 Mar 3;364(9):806–17.

Dabigatran (Pradaxa)

RE-LY Studie

Wirksamkeit



No. at Risk						
Warfarin	6022	5862	5718	4593	2890	1322
Dabigatran, 110 mg	6015	5862	5710	4593	2945	1385
Dabigatran, 150 mg	6076	5939	5779	4682	3044	1429

Figure 1. Cumulative Hazard Rates for the Primary Outcome of Stroke or Systemic Embolism, According to Treatment Group.

Sicherheit

Table 3. Safety Outcomes, According to Treatment Group.*

Event	Dabigatran, 110 mg		Dabigatran, 150 mg		Warfarin		Dabigatran, 110 mg, vs. Warfarin		Dabigatran, 150 mg, vs. Warfarin		Dabigatran, 150 mg vs. 110 mg	
							Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value
	no. of patients	*%/yr*	*no. of patients*	*%/yr*	*no. of patients*	*%/yr*						
Major bleeding	322	2.71	375	3.11	397	3.36	0.80 (0.69–0.93)	0.003	0.93 (0.81–1.07)	0.31	1.16 (1.00–1.34)	0.052
Life threatening	145	1.22	175	1.45	212	1.80	0.68 (0.55–0.83)	<0.001	0.81 (0.66–0.99)	0.04	1.19 (0.96–1.49)	0.11
Non–life threatening	198	1.66	226	1.88	208	1.76	0.94 (0.78–1.15)	0.56	1.07 (0.89–1.29)	0.47	1.14 (0.95–1.39)	0.17
Gastrointestinal†	133	1.12	182	1.51	120	1.02	1.10 (0.86–1.41)	0.43	1.50 (1.19–1.89)	<0.001	1.36 (1.09–1.70)	0.007
Minor bleeding	1566	13.16	1787	14.84	1931	16.37	0.79 (0.74–0.84)	<0.001	0.91 (0.85–0.97)	0.005	1.16 (1.08–1.24)	<0.001
Major or minor bleeding	1740	14.62	1977	16.42	2142	18.15	0.78 (0.74–0.83)	<0.001	0.91 (0.86–0.97)	0.002	1.16 (1.09–1.23)	<0.001
Intracranial bleeding	27	0.23	36	0.30	87	0.74	0.31 (0.20–0.47)	<0.001	0.40 (0.27–0.60)	<0.001	1.32 (0.80–2.17)	0.28
Extracranial bleeding	299	2.51	342	2.84	315	2.67	0.94 (0.80–1.10)	0.45	1.07 (0.92–1.25)	0.38	1.14 (0.97–1.33)	0.11
Net clinical benefit outcome‡	844	7.09	832	6.91	901	7.64	0.92 (0.84–1.02)	0.10	0.91 (0.82–1.00)	0.04	0.98 (0.89–1.08)	0.66

SJ Connolly et al. N Engl J Med 2009; 361:1139-1151

Rivaroxaban (Xarelto)

ROCKET AF Studie

Wirksamkeit



Sicherheit

Table 3. Rates of Bleeding Events.*

Variable	Rivaroxaban (N=7111)		Warfarin (N=7125)		Hazard Ratio (95% CI)†	P Value‡
	Events	Event Rate	Events	Event Rate		
	no. (%)	*no./100 patient-yr*	*no. (%)*	*no./100 patient-yr*		
Principal safety end point: major and nonmajor clinically relevant bleeding§	1475 (20.7)	14.9	1449 (20.3)	14.5	1.03 (0.96–1.11)	0.44
Major bleeding						
Any	395 (5.6)	3.6	386 (5.4)	3.4	1.04 (0.90–1.20)	0.58
Decrease in hemoglobin ≥2 g/dl	305 (4.3)	2.8	254 (3.6)	2.3	1.22 (1.03–1.44)	0.02
Transfusion	183 (2.6)	1.6	149 (2.1)	1.3	1.25 (1.01–1.55)	0.04
Critical bleeding¶	91 (1.3)	0.8	133 (1.9)	1.2	0.69 (0.53–0.91)	0.007
Fatal bleeding	27 (0.4)	0.2	55 (0.8)	0.5	0.50 (0.31–0.79)	0.003
Intracranial hemorrhage	55 (0.8)	0.5	84 (1.2)	0.7	0.67 (0.47–0.93)	0.02
Nonmajor clinically relevant bleeding	1185 (16.7)	11.8	1151 (16.2)	11.4	1.04 (0.96–1.13)	0.35

Patel et al. N Engl J Med 2011;365:883-91

Apixaban (Eliquis)

ARISTOTLE Studie

Gesamtmortalität unter Apixaban -11%, p<0.05

Wirksamkeit



Sicherheit



Granger CB et al. N Engl J Med. 2011 15;365(11):981

Edoxaban (Lixiana)

ENGAGE-AF Studie

Wirksamkeit



Sicherheit



ENGAGE AF-TIMI 48

Vergleich der NOAK

	Event Rate per 100 person-years		Hazard Ratio (95% CI)	p value
	Apixaban	vs. Warfarin		
	n=7,695	n=7,695		
S/SE	1.33	1.66	0.67 (0.46–0.98)	0.04
Ischemic	1.03	1.05	0.83 (0.53–1.29)	0.40
Hemorrhagic	0.19	0.46	0.35 (0.14–0.88)	0.03
	Dabigatran	vs. Warfarin		
	n=14,307	n=14,307		
S/SE	1.18	1.22	0.98 (0.76–1.26)	0.88
Ischemic	0.92	0.88	1.06 (0.79–1.42)	0.70
Hemorrhagic	0.16	0.29	0.56 (0.30–1.04)	0.07
	Rivaroxaban	vs. Warfarin		
	n=16,175	n=16,175		
S/SE	1.26	1.29	0.93 (0.72–1.19)	0.56
Ischemic	0.95	0.88	1.01 (0.75–1.36)	0.95
Hemorrhagic	0.21	0.32	0.61 (0.35–1.07)	0.08

Favor NOAC 1.0 Favor Warfarin

	Event Rate per 100 person-years		Hazard Ratio (95% CI)	p value
	Apixaban	vs. Warfarin		
	n=7,695	n=7,695		
Major Bleeding	2.33	4.46	0.45 (0.34 – 0.59)	<0.001
Intracranial	0.29	1.06	0.24 (0.12 – 0.50)	<0.001
Gastrointestinal	1.78	3.04	0.51 (0.37 – 0.70)	<0.001
	Dabigatran	vs. Warfarin		
	n=14,307	n=14,307		
Major Bleeding	2.37	3.03	0.79 (0.67 – 0.94)	<0.01
Intracranial	0.28	0.79	0.36 (0.23 – 0.56)	<0.001
Gastrointestinal	1.97	1.95	1.03 (0.84 – 1.26)	0.78
	Rivaroxaban	vs. Warfarin		
	n=16,175	n=16,175		
Major Bleeding	4.04	3.64	1.04 (0.90 – 1.20)	0.60
Intracranial	0.44	0.79	0.51 (0.35 – 0.75)	<0.001
Gastrointestinal	3.26	2.53	1.21 (1.02 – 1.43)	0.03

Favor NOAC 1.0 Favor Warfarin

Yao X et al. Journal of the American Heart Association. 2016:13;5

NOAK Meta-Analyse

- Knapp 30’000 Patienten
- Indikation: OAK bei VHF
- Bessere efficacy (alle 4 NOAK)
- Bessere safety (alle ausser Rivaroxaban)
- Reduzierte Gesamtmortalität (alle 4 NOAK)
- Unterschiede bei den NOAK!



Figure 1: **Stroke or systemic embolic events**
Data are n/N, unless otherwise indicated. Heterogeneity: I^2=47%; p=0·13. NOAC=new oral anticoagulant. RR=risk ratio. *Dabigatran 150 mg twice daily. †Rivaroxaban 20 mg once daily. ‡Apixaban 5 mg twice daily. §Edoxaban 60 mg once daily.



Figure 3: **Major bleeding**
Data are n/N, unless otherwise indicated. Heterogeneity: I^2=83%; p=0·001. NOAC=new oral anticoagulant. RR=risk ratio. *Dabigatran 150 mg twice daily. †Rivaroxaban 20 mg once daily. ‡Apixaban 5 mg twice daily. §Edoxaban 60 mg once daily.



Figure 2: **Secondary efficacy and safety outcomes**
Data are n/N, unless otherwise indicated. Heterogeneity: ischaemic stroke I^2=32%, p=0·22; haemorrhagic stroke I^2=34%, p=0·21; myocardial infarction I^2=48%, p=0·13; all-cause mortality I^2=0%, p=0·81; intracranial haemorrhage I^2=32%, p=0·22; gastrointestinal bleeding I^2=74%, p=0·009. NOAC=new oral anticoagulant. RR=risk ratio.

Lancet 2014; 383:955-62

Baseline Charakteristika

	RE-LY[a] (Dabigatran)	ROCKET-AF[b] (Rivaroxaban)	ARISTOTLE[c] (Apixaban)	ENGAGE AF[d] (Edoxaban)
Randomized, N	18,113	14,264	18,201	21,105
Age, y	72 ± 9	73 [65-78]	70 [63-76]	72 [64-78]
Female, %	37	40	35	38
Paroxysmal AF, %	32	18	15	25
VKA naive, %	50	38	43	41
Aspirin use,%	40	36	31	29



a) Connolly SJ et al. NEJM 2009;361:1139–51 | b) Patel MR et al. NEJM 2011;365:883–91 | c) Granger CB et al. NEJM 2011;365:981–92 | d) Giuliano RP et al. NEJM 2013;369:2093

Schlussfolgerung

- ✓ Bisher gibt es keine vergleichenden Untersuchungen, die eine wissenschaftlich begründete Präferenz für eine der neuen oralen Antikoagulantien rechtfertigen würde.
- ✓ Hinsichtlich der Blutungskomplikationen scheint Apixaban günstiger als Dabigatran, Rivaroxaban und Edoxaban zu sein.
- ✓ Generell haben alle NOAK´s in Metaanalysen hinsichtlich von Hirnblutungen einen Vorteil gegenüber von Vitamin K Antagonisten (VKA).
- ✓ Allerdings sind gastrointestinale Blutungen unter einer NOAK Behandlung häufiger als bei VKA.

Unterschiede in der Elimination



Pharmakokinetik

	Dabigatran[158,182]	**Apixaban**[183]	**Edoxaban**[184]	**Rivaroxaban**[185,186]
Bioavailability	3–7%	50%	62%	15 mg/20 mg: 66% without food, 80–100% with food
Prodrug	Yes	No	No	No
Clearance non-renal/renal of absorbed dose	20%/80%	73%/27%	50%/50%	65%/35%
Plasma protein binding	35%	87%	55%	95%
Dialysability	50–60% (in part dialysable)	14% (in part dialysable)	n.a. (in part dialysable)	n.a. (in part dialysable)
Liver metabolism: CYP3A4 involved	No	Yes [elimination, moderate contribution (≈25%)[a]]	Minimal (<4% of elimination)	Yes (hepatic elimination ≈18%)[131]
Absorption with food	No effect	No effect	6-22% more; minimal effect on exposure	+39% more (see above)
Absorption with H2B/PPI	-12% to 30% (not clinically relevant)	No effect	No effect	No effect
Asian ethnicity	+25%[166]	No effect	No effect	No effect
Elimination half-life	12–17 h	12 h	10–14 h	5–9 h (young)
				11–13 h (elderly)
Other	Dyspepsia (5–10%)			Intake of 15 mg/20 mg with food mandatory

Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

Alter = Blutungsrisiko

	Stroke/Systemic Thromboembolism, %/y		Major Bleeding	
	Age < 75 y	Age > 75 y	Age < 75 y	Age > 75 y
RE-LY				
Dabigatran 150 mg	0.9	1.4	2.1	5.1
Warfarin	1.4	2.1	3.0	4.4
ROCKET-AF				
Rivaroxaban	2	2.3	2.7	4.9
Warfarin	2.1	2.9	2.8	4.4
ARISTOTLE				
Apixaban	1.2	1.6	2.0	3.3
Warfarin	1.7	2.2	2.8	5.2
ENGAGE-TIMI 48				
Edoxaban -- higher dose	1.7	1.9	2.5	4.0
Warfarin	1.8	2.3	3.3	4.8

Turagam et al. *Clin Interv Aging*. 2015;10:1431–44

Medikamenteninteraktionen

Drug	Avoid Use	No Specific Recommendations	No Adjustment Needed	CrCl 30 to 50 mL/min	Dose Reduction
Carbamazepine	A D R	E			
Clarithromycin		E	D R		A 2.5 mg twice daily*
Dronedarone		A R	E	D 75 mg twice daily	
Itraconazole	R	E	D		A 2.5 mg twice daily*
Ketoconazole	A R	E		D 75 mg twice daily	A 2.5 mg twice daily*
Phenytoin	A D R	E			
Rifampin	A D E R				
Ritonavir	R	E	D		A 2.5 mg twice daily*
St. John's wort	A D R	E			

*If on 2.5 mg twice daily, discontinue apixaban

Apixaban Dabigatran Edoxaban Rivaroxaban

Kovacs RJ, et al. *J Am Coll Cardiol.* 2015;65:1340-1360.

Medikamenteninteraktionen

	Via	Dabigatran etexilate	Apixaban	Edoxaban	Rivaroxaban
P-gp substrate		Yes	Yes	Yes	Yes
CYP3A4 substrate		No	Yes (≈25%)	No (<4%)	Yes (≈18%)[131]
Antiarrhythmic drugs					
Amiodarone	moderate P-gp competition	+12 to 60%[SmPC]	No PK data[a]	+40%[132–134]	Minor effect[a]
Digoxin	P-gp competition	No effect[SmPC]	No effect[135]	No effect	No effect[SmPC]
Diltiazem	P-gp competition and weak CYP3A4 inhibition	No effect[SmPC]	+40%[136]	No data yet	No effect
Dronedarone	P-gp competition and CYP3A4 inhibition	+70 to 100% (US: 2 × 75 mg if CrCl 30–50 mL/min)	No PK or PD data: caution	+85%[b]	Moderate effect, should be avoided
Quinidine	P-gp competition	+53%[SMPC]	No data yet	+77%[137] (no dose reduction required by label)	Extent of increase unknown
Verapamil	P-gp competition (and weak CYP3A4 inhibition)	+12 to 180%[SmPC] (if taken simultaneously)	No PK data	+53% (SR)[137,142] (no dose reduction required by label)	No effect
Other cardiovascular drugs					
Atorvastatin	P-gp competition and CYP3A4 inhibition	No relevant interaction	No data yet	No effect	No effect
Ticagrelor	P-gp competition	+25%[SmPC] (give loading dose 2h after dabigatran)[d]	No data	No data	No data
Antibiotics					
Clarithromycin; Erythromycin	Moderate P-gp competition and strong CYP3A4 inhibition	+15 to 20%	+60% AUC +30% C_{max}	+90%[SmPC]	+34% (Erythromycin)/ +54% (Clarithromycin) [SmPC129]
Rifampicin	P-gp/BCRP and CYP3A4/ CYP2J2 inducers	Minus 66%[SmPC]	Minus 54%[138]	Minus 35%, but with compensatory increase of active metabolites	Up to minus 50%[SmPc]
Antiviral drugs					
HIV protease inhibitors (e.g. ritonavir)	P-gp and BCRP competition or inducer; CYP3A4 inhibition	No data yet	Strong increase[SmPC]	No data yet	Up to +153%[129]

Fungostatics					
Fluconazole	Moderate CYP3A4 inhibition	No data yet	No data yet	No data yet	+42% (if systemically administered)[SmPC]
Itraconazole; Ketoconazole; Voriconazole	potent P-gp and BCRP competition; CYP3A4 inhibition	+140 to 150% (US: 2 x 75 mg if CrCl 30–50 mL/ min)	+100%[136]	+87 to 95%[132] (reduce NOAC dose by 50%)	Up to +160%[SmPc]
Posaconasole	Mild to moderate P-gp inhibition	SmPC	SmPC		SmPC
Others					
Naproxen	P-gp competition; pharmacodynamically increased bleeding time	No data yet	+55%[139]	No effect	No data yet
H2B; PPI; Al-mg-hydroxide	GI absorption	Minus 12–30%	No effect	No effect[SmPc]	No effect[140]
St. John's wort	P-gp/BCRP and CYP3A4/ CYP2J2 inducers				
Other factors					
Age ≥80 years	Potential for Increased plasma levels		b	c	
Age ≥75 years	Potential for Increased plasma levels			c	
Weight ≤60 kg	Potential for Increased plasma levels		b	b	
Renal function	Increased plasma level	See *Figure 4*			
Other increased bleeding risk		• Concomitant antiplatelet drugs; NSAID; systemic steroid therapy; other anticoagulants • History of GI bleeding • Recent surgery on critical organ (brain; eye) • Frailty/falls risk • St.p bleeding or predisposition (anaemia, thrombocytopenia)			

NOAK und Nierenfunktion



Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

NOAK bei Leberinsuffizienz

Parameters	**1 point**	**2 points**	**3 points**
Encephalopathy	No	Grade 1–2 (suppressed with medication)	Grade 3–4 (refractory/chronic)
Ascites	No	Mild (diuretic-responsive)	Moderate–severe (diuretic-refractory)
Bilirubin	<2 mg/dL	2–3 mg/dL	>3 mg/dL
	<34 μmol/L	34–50 μmol/L	>50 μmol/L
Albumin	>3.5 g/dL	2.8–3.5 g/dL	<2.8 g/dL
	>35 g/L	28–35 g/L	<28 g/dL
INR	<1.7	1.71–2.30	>2.30

Child–Pugh category	**Dabigatran**	**Apixaban**	**Edoxaban**	**Rivaroxaban**
A (5–6 points)	No dose reduction	No dose reduction	No dose reduction	No dose reduction
B (7–9 points)	Use with caution	Use cautiously	Use cautiously	Do not use
C (10–15 points)	Do not use	Do not use	Do not use	Do not use

Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

Therapeutische Breite I



Beeinflussung des Plasmaspiegels durch:

- Nierenfunktion
- Lebensalter
- Körpergewicht

Fehlende Messung der Gerinnungshemmung suggeriert falsche Sicherheit

Reilly PA et al. J Am Coll Cardiol. 2014;63(4):321

Therapeutische Breite II



Therapeutischer Bereich von VKA – Monitoring des INR-Wertes



Nach Fuster el al., *Eur Heart J*. 2006 Aug;27(16):1979-2030

Dosisanpassung

- Nicht bei allen Präparaten getestet

RE-LY[a]	ROCKET-AF[b]	ARISTOTLE[c]	ENGAGE-AF[d]
• None	• 20→15 mg/d for: – CrCl < 30-49 mL/min	• 5→2.5 mg BID for ANY 2 of: – Age ≥ 80 years – Body weight ≤ 60 kg – SCr ≥ 1.5 mg/dL	• 60→30 mg/d or 30→15 mg/d for: – CrCl 30-50 mL/min – Body weight ≤ 60 kg – Use of quinidine, verapamil, or dronedarone

a. Connolly SJ, et al. *N Engl J Med*. 2009;361:1139-1151; b. Patel MR, et al. *N Engl J Med*. 2011;365:883-891;
c. Granger CB, et al. *N Engl J Med*. 2011;365:981-992; d. Giugliano RP, et al. *N Engl J Med*. 2013;369:2093-2104.

Qualität der OAK

- The SAMe-TT_2R_2 score

Acronym	Definitions	Points
S	Sex (female)	1
A	Age (< 60 y)	1
M	Medical history[a]	1
e		
T	Treatment (interacting drugs, eg, amiodarone for rhythm control)	1
T	Tobacco use (within 2 y)	2
R	Race (nonwhite)	2
Maximum points		8

Prediction of poor INR control

SAMe-TT2R2 score 0-1 → good

SAMe-TT2R2 score ≥2 → poor

More than two of the following: hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, and hepatic or renal disease.

Apostolakis S et al. Chest 2013;144:1555–1563

Wahl des NOAK



Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

Wechsel von OAK zu NOAK



Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

Absetzen vor elektiven Interventionen

	Dabigatran		Apixaban – Edoxaban – Rivaroxaban	
	No important bleeding risk and/or adequate local haemostasis possible: perform at trough level (i.e. 12 h or 24 h after last intake)			
	Low risk	**High risk**	**Low risk**	**High risk**
CrCl ≥80 mL/min	≥24 h	≥48 h	≥24 h	≥48 h
CrCl 50–79 mL/min	≥36 h	≥72 h	≥24 h	≥48 h
CrCl 30–49 mL/min	≥48 h	≥96 h	≥24 h	≥48 h
CrCl 15–29 mL/min	Not indicated	Not indicated	≥36 h	≥48 h
CrCl <15 mL/min	No official indication for use			
No bridging with LMWH/UFH				
Resume full dose of NOAC ≥24 h post-low bleeding risk interventions and 48 (–72) h post-high-bleeding risk interventions (see also *Figure 8*)				
Patients undergoing a planned intervention should receive a written note indicating the anticipated date and time of their intervention, and the date and time of the last intake of their NOAC (and any other medication)				

Interventions with minor bleeding risk
Dental interventions
Extraction of 1–3 teeth
Paradontal surgery
Incision of abscess
Implant positioning
Cataract or glaucoma intervention
Endoscopy without biopsy or resection
Superficial surgery (e.g. abscess incision; small dermatologic excisions; . . .)
Interventions with low bleeding risk (i.e. infrequent or with low clinical impact)
Endoscopy with biopsy
Prostate or bladder biopsy
Electrophysiological study or catheter ablation (except complex procedures, see below)
Non-coronary angiography (for coronary angiography and ACS: see Patients undergoing a planned invasive procedure, surgery or ablation section)
Pacemaker or ICD implantation (unless complex anatomical setting, e.g. congenital heart disease)
Interventions with high bleeding risk (i.e. frequent and/or with high impact)
Complex endoscopy (e.g. polypectomy, ERCP with sphincterotomy etc.)
Spinal or epidural anaesthesia; lumbar diagnostic puncture
Thoracic surgery
Abdominal surgery
Major orthopaedic surgery
Liver biopsy
Transurethral prostate resection
Kidney biopsy
Extracorporeal shockwave lithotripsy (ESWL)
Interventions with high bleeding risk AND increased thromboembolic risk
Complex left-sided ablation (pulmonary vein isolation; some VT ablations)

Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

Probleme mit (N)OAK

- Bei bis zu 44% aller Patienten bestehen **Kontraindikationen** für eine OAK.
- Die **Abbrecherquote** bei antikoagulierten Patienten beträgt 38% pro Jahr. (Komplikationen, Unverträglichkeit)
- INR-Wert bei 30-46% der Messungen ausserhalb des Zielbereichs (Interaktionen, alimentäre Vitamin-K-Schwankungen, schlechte Einnahmedisziplin)
- Die mittlere Rate anämisierender **Blutungen** unter OAK beträgt pro Jahr 1.4%. Bei Patienten über 80 Jahre steigt diese auf über 4% pro Jahr an.
- **NOAK** sind zwar z.T. effizienter als Vitamin-K-Antagonisten in Bezug auf die Senkung der CVI-Rate und einfacher einzustellen, die **Blutungsproblematik** ist jedoch kompliziert (keine Aktivitätsbestimmung, kein Antidot).

Blutungsrisiko unter OAK

- Blutungen unter OAK
  - schwere Blutungen 2-22% pro Jahr
  - fatale Blutungen 2-9% pro Jahr
  - OAK-bezogener Tod
    - 5% nach 1 Jahr
    - 7% nach 2 und 3 Jahren

- Alter ist ein Risikofaktor für Blutungen
  - Schlechtere Compliance
  - Nutritiver Vitamin K Mangel
  - Polypharmazie

Kumulatives Blutungsrisiko

Cumulative risk of a first event of major bleeding and of any bleeding



(N)OAK in TVT

Annual rates of major haemorrhage with warfarin

Study	Year published	Population (*n*)	Major haemorrhage, % per year	ICH % per year
Randomised trials				
AFI[18]	1994	AF ($n = 3691$)	1.3	0.3
SPAF II[19] (2 age strata)	1994	AF ($n = 715$)	1.7	0.5
		AF ($n = 385$)	4.2	1.8
AFFIRM[20]	2002	AF ($n = 4060$)	2.0	0.6
SPORTIF III[21]	2003	AF ($n = 3407$)	2.2	0.4
SPORTIF V[22]	2005	AF ($n = 3422$)	3.4	0.1
ACTIVE W[23]	2006	AF ($n = 6706$)	2.2	NR
RE-LY[24]	2009	AF ($n = 18006$)	3.4	0.74
ROCKET-AF[25]	Presented 2010	AF ($n = 14264$)	3.5	0.7
Inception cohort				
Landefeld and Goldman[26]	1989	All ($n = 565$)	7.4	1.3
Steffensen *et al.*[27]	1997	All ($n = 682$)	6.0	1.3
Beyth *et al.*[28]	1998	All ($n = 264$)	5.0	0.9
Pengo *et al.*[29]	2001	AF ($n = 433$)	Age $\geq$ 75: 5.1	NA
			Age $<$ 75: 1.0	
Hylek *et al.*[30]	2007	AF ($n = 472$)	7.2	2.5
Non-inception cohort (prevalent warfarin use)				
Van der Meer*et al.*[31]	1993	All ($n = 6814$)	2.7	1.3
Fihn *et al.*[32]	1996	All ($n = 928$)	1.0	1.3
ATRIA[33]	2003	AF ($n = 6320$)	1.52	0.46
Poli *et al.*[34]	2009	AF ($n = 783$)	1.4	2.5
Rose *et al.*[35]	2009	AF ($n = 3396$)	1.9	NA

OAK in aFib

Schulman S et al. NEJM 2009 | Lip GYH et al. Europace 2011

Lebenslanges Blutungsrisiko



Extrapoliert



Jährliche Blutungsrate (HAS-BLED-Score)

0.8% in the low-risk group (0–3 points)

2.6% in medium risk (4 points)

5.8% in high risk (5–10 points)

Schulman S et al. NEJM 2009

OAK + ASS

	RE-LY			ROCKET-AF		ARISTOTLE		ENGAGE AF-TIMI 48			Combined	
	Dabigatran 150 mg (n = 6076)	Dabigatran 110 mg (n = 6015)	Warfarin (n = 6022)	Rovaroxaban (n = 7131)	Warfarin (n = 7133)	Apixaban (n = 9120)	Warfarin (n = 9081)	Edoxaban 60 mg (n = 7035)	Edoxaban 30 mg (n = 7034)	Warfarin (n = 7036)	NOAC (n = 42,411)	Warfarin (n = 29,272)
Aspirin at baseline, %	39	40	41	36	37	31	31	29	29	30	34	34

Ruff CT, et al. *Lancet.* 2014;383:955-962.

(N)OAK + DAPT

- DAPT + OAK = 2-3 faches Blutungsrisiko
- Indikation für OAK re-evaluieren!
- HAS-BLED Score
  - Hypertonie, Nieren- u. Leberfunktion, Stroke, Blutungsanamnese, labiler INR, Alter, Medikamente, C2
  - optimieren des Blutungsrisikos (PPI, etc.)
  - keine Abwägung gegen CHA_2DS_2-Vasc-Score
- Bisher WOEST-Schema

• Assess ischaemic and bleeding risks using validated risk predictors (e.g. CHA_2DS_2-VASc, ABC, HAS-BLED) with a focus on modifiable risk factors.
• Keep triple therapy duration as short as possible; dual therapy after PCI (oral anticoagulant and clopidogrel) to be considered instead of triple therapy.
• Consider the use of NOACs instead of VKA.
• Consider a target INR in the lower part of the recommended target range and maximize time in therapeutic range (i.e. > 65–70%) when VKA is used.
• Consider the lower NOAC regimen tested in approval studies and apply other NOAC regimens based on drug-specific criteria for drug accumulation.[a]
• Clopidogrel is the $P2Y_{12}$ inhibitor of choice.
• Use low-dose (≤ 100 mg daily) aspirin.
• Routine use of PPIs.

Die Qual der Wahl 3



Factors to shorten combination therapy

- (Uncorrectable) high bleeding risk
- Low atherothrombotic risk (by REACH or SYNTAX score if elective; GRACE ≥140 if ACS)

Factors to lengthen combination therapy

- First-generation DES
- High atherothrombotic risk (scores as above ; stenting of the left main, proximal LAD, proximal bifurcation; recurrent MIs; stent thrombosis etc.) and low bleeding risk

Steffel J et al. Eur Heart J. 2018 Apr 21;39(16):1330–93.

(N)OAK + DAPT

PIONEER AF-PCI: Rivaroxaban



sig. weniger Blutungen in den 2 Rivaroxaban Gruppen
underpowered bzgl. ischämischer Ereignisse

WOEST: Marcoumar



- Primary outcome measure: combination of TIMI and GUSTO minor and major bleeding up to 30 days and 1 year
- Secondary outcome measure: MACE

Dewilde W, et al. *Am Heart J*. 2009;158:713-718.

RE-DUAL-PCI: Dabigatran



- Primary outcome measure: Time to first ISTH major bleeding or CRNM bleeding event
- Secondary endpoints: Composite of all cause death or thrombotic events (MI, or stroke/SE) and unplanned revascularization

Cannon CP, et al. *Clin Card*. 2016; 39:555-564.

ENTRUST-AF-PCI: Edoxaban



- Primary outcome measure: ISTH major or CRNM bleeding
- Secondary outcome measure: composite of CV death, stroke, SEE, MI or definite stent thrombosis

AUGUSTUS: Apixaban



- P2Y12 inhibitor for all patients x 6 months
- Aspirin for all on the day of ACS or PCI
- Aspirin vs placebo after randomization

Neue Risiken

- Erhöhtes Risiko für rezidivierende thrombotische Ereignisse unter NOAK beim Antiphospholipid-Syndrom (APS)
  - Antikörper gegen
    - Cardiolipin
    - Anti-beta-2-Glycoprotein

- Umstellung auf Marcoumar



P.P. 6343 Rotkreuz Post CH AG

Herr
PD Dr. med. Gregor Leibundgut
Medizinische Universitätsklinik
Kardiologie
Rheinstrasse 26
4410 Liestal

WICHTIGE MITTEILUNG ZUR ARZNEIMITTELSICHERHEIT

Im Juli 2019

Sehr geehrter Herr Doktor Leibundgut

Apixaban (Eliquis), Dabigatranetexilat (Pradaxa), Edoxaban (Lixiana) und Rivaroxaban (Xarelto, Xarelto vascular): Die Anwendung wird bei Patienten mit Antiphospholipid-Syndrom aufgrund eines möglicherweise erhöhten Risikos für rezidivierende thrombotische Ereignisse nicht empfohlen.

Die Bayer (Schweiz) AG, Boehringer Ingelheim (Schweiz) GmbH, Bristol-Myers Squibb/Pfizer und Daiichi Sankyo (Schweiz) AG möchten Sie in Abstimmung mit Swissmedic über Folgendes informieren.

Zusammenfassung

- **Ergebnissen einer multizentrischen Studie zufolge war bei Patienten mit einer Thrombose in der Vorgeschichte, bei denen ein Antiphospholipid-Syndrom (APS) diagnostiziert wurde, die Anwendung von Rivaroxaban im Vergleich zu Warfarin mit einem erhöhten Risiko für rezidivierende thrombotische Ereignisse assoziiert. Andere DOAKs (Apixaban, Edoxaban und Dabigatranetexilat) sind möglicherweise ebenfalls im Vergleich zu Vitamin-K-Antagonisten, wie Warfarin oder Phenprocoumon, mit einem erhöhten Risiko für rezidivierende Thrombosen assoziiert.**
- **Die Anwendung von DOAKs wird bei Patienten mit APS nicht empfohlen, besonders bei Hoch-Risiko-Patienten (Patienten, die in allen drei Antiphospholipid-Tests positiv getestet wurden – Lupus-Antikoagulans, Anti-Cardiolipin-Antikörper und Anti-Beta-2-Glykoprotein-I-Antikörper).**
- **Überprüfen Sie, ob bei Patienten mit APS, die zurzeit mit DOAKs zur Prävention thromboembolischer Ereignisse behandelt werden, eine Fortsetzung der Behandlung angemessen ist und erwägen Sie eine Umstellung auf Vitamin-K-Antagonisten. Dies gilt insbesondere für Hoch-Risiko-Patienten.**

Hintergrundinformation

Der Evidenzgrad für ein erhöhtes Risiko rezidivierender thrombotischer Ereignisse bei Patienten mit APS ist für die im Markt befindlichen direkten oralen Antikoagulanzien (DOAKs) unterschiedlich. Zum gegenwärtigen Zeitpunkt gibt es keine ausreichende Evidenz dafür, dass eines der DOAKs bei Patienten mit nachgewiesenem APS einen ausreichenden Schutz bietet. Dies gilt insbesondere für Patienten mit dem höchsten Risiko für thromboembolische Ereignisse. Die Anwendung von DOAKs bei diesen Patienten wird nicht empfohlen.

Rivaroxaban: In einer Investigator-gesponserten, randomisierten, offenen, multizentrischen Studie (TRAPS, registriert auf www.clinicaltrials.gov als #NCT02157272; Blood. 2018 Sep 27;132 (13):1365-1371) mit verblindeter Endpunkt-Adjudizierung wurde Rivaroxaban bei Patienten mit einer Thrombose in der Vorgeschichte, bei denen eine APS-Diagnose mit hohem Risiko für thromboembolische Ereignisse (konstant positiv getestet in allen drei Antiphospholipid-Tests) gestellt wurde, mit Warfarin verglichen. Die Studie wurde nach Einschluss von 120

Komplexität

Digitale Hilfe?

- Input
  - Indikationen
  - Laborwerte
  - Diagnosen
  - Risk Scores
  - Interaktionen



- Output
  - Blutungsrisiko und Ischämierisiko
  - Medikament und Dosierung

Generelle Empfehlung

1. Schlaganfallrisiko abschätzen (CHA_2DS_2-VASc)

   ≥ 1 Punkt → (N)OAK

2. Blutungsrisiko abschätzen (HAS-BLED)

   Modifizierbare Faktoren identifizieren und behandeln

   Unkontrollierte Hypertonie, Anämia, Niereninsuffizienz, labiler INR, gleichzeitige Einnahme von Aspirin or NSAR, Alkoholmissbrauch, Thrombozytopenie, and erhöhtes Sturzrisiko

3. Bei zusätzlicher DAPT Rücksprache mit Kardiologe/Interventionalist

4. Jährliche Re-Evaluation

Welches NOAK für Welche Diagnose?



A = Apixaban | D = Dabigatran | E = Edoxaban | R = Rivaroxaban

Lip G et al. JACC 2015;21:2282

Individualisiertes NOAK

	Dabigatran	Apixaban	Edoxaban	Rivaroxaban
Standard dosing*	150 mg or 110 mg twice daily	5 mg twice daily	60 mg once daily	20 mg once daily
Dose adjustment in patients with chronic kidney disease and for age, weight, co-medication*	No (creatinine clearance <30 mL/min contraindicated)	2.5 mg twice daily in patients with atrial fibrillation and severe chronic kidney disease (creatinine clearance 15–29 mL/min) or at least 2 of the following criteria: age ≥ 80 years; body weight ≤ 60 kg or serum creatinine ≥ 1.5 mg/dL	30 mg once daily, in the presence of the following factors: Creatinine clearance 15–49 mL/min, body weight ≤ 60 kg, co-medication with cyclosporine, dronedarone, erythromycin or ketoconazole	15 mg once daily in patients with atrial fibrillation, if creatinine clearance 15–49 mL/min
Bioavailability	3–7%	50%	62%	66% without food, almost 100% with food
Prodrug	Yes	No	No	No
Non-renal/renal clearance of the absorbed dose (with normal renal function)	20% / 80%	73% / 27%	50% / 50%	65% / 35%
Hepatic drug metabolism: CYP450 involved	No	Yes (elimination; low CYP3A4 involvement)	minimal (<10% of elimination)	Yes (elimination)
Absorption with concomitant food intake	No effect	No effect	No effect	+39% more
Recommended to take with food?	No	No	No	Compulsory
Absorption with H2 blocker/ proton pump inhibitor treatment	–12–30%	No effect	No effect	No effect
Asian patients	+25%	No effect	No effect	No effect
Gastrointestinal tolerability	Dyspepsia 5–10%	No problems	No problems	No problems
Elimination half-life	12–17 hrs	12 hrs	9–11 hrs	5–9 hrs (younger) 11–13 hrs (older)
Specific antidote available	Yes	Yes	Yes	Yes

gregor.leibundgut@ksbl.ch